BidaskClub upgraded shares of PRA Health Sciences (NASDAQ:PRAH) from a buy rating to a strong-buy rating in a research note issued to investors on Tuesday.

A number of other equities analysts also recently weighed in on PRAH. Robert W. Baird reiterated a buy rating and issued a $88.00 target price on shares of PRA Health Sciences in a report on Monday, October 9th. Credit Suisse Group reiterated an outperform rating and issued a $90.00 target price (up previously from $84.00) on shares of PRA Health Sciences in a report on Monday, October 16th. Jefferies Group reiterated a buy rating and issued a $95.00 target price on shares of PRA Health Sciences in a report on Thursday, October 26th. SunTrust Banks reiterated a buy rating and issued a $101.00 target price on shares of PRA Health Sciences in a report on Friday, October 27th. Finally, KeyCorp reiterated a buy rating and issued a $93.00 target price (up previously from $86.00) on shares of PRA Health Sciences in a report on Monday, October 30th. Three investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of Buy and a consensus target price of $91.77.

PRA Health Sciences (PRAH) opened at $93.50 on Tuesday. The firm has a market capitalization of $5,930.00, a PE ratio of 52.53, a PEG ratio of 1.28 and a beta of 0.41. PRA Health Sciences has a twelve month low of $54.44 and a twelve month high of $95.63. The company has a quick ratio of 1.01, a current ratio of 1.01 and a debt-to-equity ratio of 1.38.

PRA Health Sciences (NASDAQ:PRAH) last issued its earnings results on Wednesday, October 25th. The medical research company reported $0.88 earnings per share for the quarter, beating analysts’ consensus estimates of $0.85 by $0.03. The company had revenue of $494.55 million for the quarter, compared to the consensus estimate of $477.89 million. PRA Health Sciences had a return on equity of 21.66% and a net margin of 5.64%. The firm’s quarterly revenue was up 23.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.64 EPS. sell-side analysts forecast that PRA Health Sciences will post 3.2 earnings per share for the current fiscal year.

In related news, VP Linda Baddour sold 67,000 shares of the stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $90.27, for a total value of $6,048,090.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider David W. Dockhorn sold 72,850 shares of the stock in a transaction that occurred on Thursday, December 28th. The stock was sold at an average price of $90.83, for a total value of $6,616,965.50. The disclosure for this sale can be found here. Insiders sold 217,815 shares of company stock worth $19,690,710 in the last 90 days. 2.10% of the stock is currently owned by corporate insiders.

A number of large investors have recently added to or reduced their stakes in PRAH. IFP Advisors Inc increased its holdings in PRA Health Sciences by 19,083.3% in the fourth quarter. IFP Advisors Inc now owns 1,151 shares of the medical research company’s stock worth $105,000 after buying an additional 1,145 shares during the last quarter. Carroll Financial Associates Inc. increased its holdings in PRA Health Sciences by 127.4% in the third quarter. Carroll Financial Associates Inc. now owns 1,410 shares of the medical research company’s stock worth $112,000 after buying an additional 790 shares during the last quarter. Comerica Bank acquired a new position in PRA Health Sciences in the third quarter worth approximately $214,000. Vident Investment Advisory LLC acquired a new position in PRA Health Sciences in the third quarter worth approximately $247,000. Finally, Jennison Associates LLC bought a new stake in PRA Health Sciences during the third quarter worth approximately $252,000. Hedge funds and other institutional investors own 98.20% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this piece of content on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark laws. The legal version of this piece of content can be accessed at https://theolympiareport.com/2018/01/26/pra-health-sciences-prah-raised-to-strong-buy-at-bidaskclub.html.

About PRA Health Sciences

PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

Analyst Recommendations for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.